Cheryl Wong Po Foo

Cheryl Wong Po Foo

Cheryl Wong Po Foo, PhD, Director of Clinical Development, Audentes Therapeutics, responsible for the advancement of the clinical development program for Pompe disease.

New ERT For Late-onset Pompe Disease Shows Promise

New ERT For Late-onset Pompe Disease Shows Promise

Results from the COMET study were recently reported showing neoGAA (avalglucosidase alfa), the newer enzyme replacement therapy (ERT) currently in development, to be as effective as the currently approved ERT, Myozyme (alglucosidase alfa), in persons with late-onset Pompe disease.